(Q33798432)

29 July 2017

0 references

1 reference

title

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis (English)

1 reference

29 July 2017

1 reference

Gang Huang

1

1 reference

29 July 2017

Jun-bo Xu

2

1 reference

29 July 2017

Jian-xiong Liu

3

1 reference

29 July 2017

Yong He

4

1 reference

29 July 2017

Xiao-li Nie

5

1 reference

29 July 2017

Qiu Li

6

1 reference

29 July 2017

Yong-mei Hu

7

1 reference

29 July 2017

Si-qin Zhao

8

1 reference

29 July 2017

Mian Wang

9

1 reference

29 July 2017

Wen-yong Zhang

10

1 reference

29 July 2017

Xiao-rong Liu

11

1 reference

29 July 2017

Tao Wu

12

1 reference

29 July 2017

Akram Arkin

13

1 reference

29 July 2017

Ting-jie Zhang

14

1 reference

29 July 2017

language of work or name

1 reference

20 January 2011

1 reference

European Journal of Clinical Investigation

29 July 2017

published in

1 reference

29 July 2017

volume

41

1 reference

29 July 2017

issue

7

1 reference

29 July 2017

page(s)

719-733

1 reference

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Losartan and prevention of atrial fibrillation recurrence in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Valsartan for prevention of recurrent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Uncertainty in heterogeneity estimates in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02460.X

10.1111/J.1365-2362.2010.02460.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference